GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: EYP-001 | EYP001 | PLX-007 | PLX007
Compound class:
Synthetic organic
Comment: Vonafexor (EYP001) is an oral farnesoid X receptor (NR1H4) agonist [2].
|
|
References |
1. Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, Laveille C, Radreau-Pierini P, Darteil R, Vonderscher J et al.. (2021)
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat, 28 (12): 1690-1698. [PMID:34467593] |
2. Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. (2020)
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs, 29 (6): 623-632. [PMID:32552182] |
3. Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R et al.. (2023)
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol, 78 (3): 479-492. [PMID:36334688] |
4. Tang Y, Fan Y, Wang Y, Wang D, Huang Q, Chen T, Cao X, Wen C, Shen X, Li J et al.. (2024)
A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development. Biomed Pharmacother, 175: 116658. [PMID:38701562] |